Skip to content

US · NERV · BIOTECHNOLOGY

Minerva Neurosciences, Inc. (NERV) intrinsic value and stock valuation

$2.00as of 2026-11-21 · Mkt cap 30.42M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Minerva Neurosciences, Inc. DCF and intrinsic value

InvestorsCraft values NERV with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NERV’s statements →

Minerva Neurosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burlington, MA 01803 minervaneurosciences.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-293.42M
20112025
Free cash flow
-$-13.51B
20122025
Total equity
-$-140.75M
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-15.1M-$-21.85M-$-23.12M-$-25.23M-$-45.37M
Net income-$-293.42M$1.44M-$-30.01M-$-32.11M-$-49.91M
EPSd-$-34.68M$190.2K-$-4.61M-$-6.01M-$-9.35M
Operating cash flow-$-13.51B-$-19.55M-$-14.78M-$-24.65M-$-24.6M
Capital expenditure$0.00$0.00$0.00-$-20K$0.00
Free cash flow-$-13.51B-$-19.55M-$-14.78M-$-24.66M-$-24.6M
Total assets$98M$37.1M$56.9M$55.1M$77.1M
Total debt$65M$0.00$0.00$0.00$0.00
Net debt-$-17.34M-$-21.36M-$-40.91M-$-36.09M-$-60.76M
Total equity-$-140.75M-$-25.69M-$-28.46M-$-20.02M$7.98M
Cash and short-term investments$82.3M$21.4M$40.9M$36.1M$60.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$5.76M$11.9M$12.7M$14.7M$32M
Selling, general and administrative expenses$9.34M$9.95M$10.4M$10.6M$13.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$15.1M$21.9M$23.1M$25.2M$45.4M
Cost and expenses$15.1M$21.9M$23.1M$25.2M$45.4M
Interest income$950K$1.27M$1.44M$560K$20K
Interest expense$0.00$4.56M$8.28M$7.41M$6.33M
Depreciation and amortization$10K$20K$30K$10K$100K
Ebitda-$-293.42M$6.02M-$-21.69M-$-24.69M-$-45.28M
Operating income-$-15.1M-$-21.85M-$-23.12M-$-25.23M-$-45.37M
Total other income/expenses, net-$-278.32M$23.3M-$-6.89M-$-6.88M-$-6.34M
Income before tax-$-293.42M$1.44M-$-30.01M-$-32.11M-$-51.71M
Income tax expense$0.00$0.00$0.00$0.00-$-1.8M
Net income-$-293.42M$1.44M-$-30.01M-$-32.11M-$-49.91M
Weighted average shares outstanding$8.46M$7.57M$6.51M$5.34M$5.34M
Weighted average diluted shares outstanding$8.46M$7.57M$6.51M$5.34M$5.34M
Balance sheet
20252024202320222021
Cash and short-term investments$82.3M$21.4M$40.9M$36.1M$60.8M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$83.1M$22.3M$42M$40.2M$62.2M
Property, plant and equipment, net$0.00$10K$10K$20K$50K
Goodwill and intangible assets$14.9M$14.9M$14.9M$14.9M$14.9M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$14.9M$14.9M$14.9M$14.9M$14.9M
Total assets$98M$37.1M$56.9M$55.1M$77.1M
Accounts payable$640K$1.61M$1.81M$970K$1.85M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.29M$2.84M$3.34M$1.38M$2.82M
Long-term debt$65M$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$236.4M$60M$82M$73.7M$66.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$238.7M$62.8M$85.4M$75.1M$69.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-688.8M-$-395.38M-$-396.82M-$-366.81M-$-334.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-140.75M-$-25.69M-$-28.46M-$-20.02M$7.98M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$65M$0.00$0.00$0.00$0.00
Net debt-$-17.34M-$-21.36M-$-40.91M-$-36.09M-$-60.76M
Cash flow statement
20252024202320222021
Net income-$-293.42M$1.44M-$-30.01M-$-32.11M-$-49.91M
Depreciation and amortization$5.44M$20K$30K$10K$100K
Stock-based compensation$1.33B$1.33M$1.97M$4.11M$5.22M
Change in working capital-$-630K-$-320K$4.94M-$-4.06M$260K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.06M-$-200K$840K-$-880K$860K
Net cash provided by operating activities-$-13.51B-$-19.55M-$-14.78M-$-24.65M-$-24.6M
Investments in property, plant and equipment$0.00$0.00$0.00-$-20K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00-$-20K$0.00
Common stock issued$74.5M$0.00$20M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$74.5B$0.00$19.6M-$0.00$60M
Net change in cash$60.9B-$-19.55M$4.82M-$-24.66M$35.4M
Cash at end of period$82.4B$21.5M$41M$36.2M$60.9M
Operating cash flow-$-13.51B-$-19.55M-$-14.78M-$-24.65M-$-24.6M
Capital expenditure$0.00$0.00$0.00-$-20K$0.00
Free cash flow-$-13.51B-$-19.55M-$-14.78M-$-24.66M-$-24.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Minerva Neurosciences, Inc.

        Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

        CEO
        Remy Luthringer
        Employees
        7
        Beta
        -0.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Minerva Neurosciences, Inc. (NERV)?

        InvestorsCraft does not currently publish an intrinsic value for NERV. How the IC value is calculated.

        Is NERV undervalued?

        InvestorsCraft does not publish an undervaluation signal for NERV at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.